An Exciting New Clinical Trial for Those who Are Resistant to ALK Inhibitors Is Recruiting Soon
Those in the ALK community fear the day when progression occurs after Lorlatinib, the “last” ALK inhibitor available. Although there are effective treatments after Lorlatinib, there is no standard treatment. Without a specified FDA-approved treatment, people must face Lorlatinib resistance without knowing the best strategy.
In the next few months, the ALKove-1 trial will begin recruiting. ALKove-1 is a trial of NVL-655, a new ALK inhibitor. This drug is specially formulated to address the common ALK resistance mutation G1202R along with several mutations that occur with Lorlatinib resistance. The first trial will be a small phase 1 trial where escalating doses will determine safety and dosing. The study locations have not been announced yet, but word should come soon. The hope is that NVL-655 will eventually become a standard FDA-approved treatment for those who no longer benefit from other ALK inhibitors.
Below is a compilation of resources that will help ALK-positive patients and their care teams identify suitable clinical trials that are open to them.
ALK LUNG CANCER CLINICAL TRIAL HELP AND SEARCHING:
ALK Positive Support Group Clinical Trials Spreadsheet*
GO2 Foundation for Lung Cancer - LUNGMATCH
LUNGevity Online Clinical Trial Finder
CenterWatch Clinical Trials Search
MassiveBio Clinical Trials Search
General Info about ALK NSCLC Clinical Trials
As of May 2022, there are at least 50 clinical trials that are recruiting specifically for people with ALK-positive lung cancer. Many of these trials have multiple sites worldwide. Since ALK-positive lung cancer is a rare disease, it is difficult for any one oncologist to be aware of all the trials available. You can advocate for yourself and find a clinical trial that may be a good fit for you at any juncture in treatment.
*The ALK Positive Clinical Trials Spreadsheet was developed by the ALK Positive Medical Committee. The database is updated monthly.
Disclaimer: these trials have been consolidated by volunteers and should not be considered exhaustive. Listing of these trials is not an endorsement, and ALK Positive does not recommend one trial over another. Please talk with your doctor about these or any trials you are interested in.
Author: Ellee Urban